Clinical Trial Update: Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

View source ↗

Summary

Clinical trial update indicates naxitamab is being added to induction therapy for high-risk neuroblastoma, with the trial currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Naxitamab (naxitamab)

Snippet

Sponsor: Guangzhou Women and Children's Medical Center | Conditions: Neuroblastoma, GD2 Antibody (Naxitamab) | Status: RECRUITING